HOME > FEATURE
FEATURE
- COMMENTARY
- COLUMN
- Drug Approval & Reimbursement in 2024
- Discussions on Next PMD Act Amendment
- Chuikyo Debate on Off-Year Drug Price Revisions
- TRENDS
- MHLW Panel on Generic Industry Structure
- MHLW Panel on Pharmaceutical Regulations
- Drug Approval & Reimbursement in 2023
- Chuikyo on FY2024 Reimbursement Reform
- MHLW Expert Panel on Comprehensive Policies
- Chuikyo on Off-Year Drug Price Revision
- FY2022 Drug Maker Employment Survey
- Jiho Survey: FY2022 Drug Price Revision
- FY2022 Drug Pricing Reform
- FY2021 Drug Maker Employment Survey
- INTERVIEW
- Generic APIs at Crossroads
- Post-Promotion Guidelines
- Impact of Oligonucleotides